Jennifer K. Simpson - 27 Mar 2023 Form 4 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role
President and CEO, Director
Signature
/s/ Joshua L. Colburn, Attorney-in-Fact
Issuer symbol
PBLA
Transactions as of
27 Mar 2023
Net transactions value
$0
Form type
4
Filing time
29 Mar 2023, 16:26:33 UTC
Previous filing
09 Mar 2023
Next filing
29 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBLA Stock Option (right to buy) Award $0 +99,383 $0.000000 99,383 27 Mar 2023 Common Stock 99,383 $0.5000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option fully vests on March 20, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.